Head-to-Head Study INCOMIN (IFN beta-1b vs beta-1a) Trial, 104 Weeks
{"Image DocumentName": "Head-to-Head Study INCOMIN (IFN beta-1b vs beta-1a) Trial, 104 Weeks", "Image ImageDescription": "Patients Relapse-Free. Difference. P Value. IFN beta-1b 250 mcg SC EOD. 51% 42% in favor of IFN beta-1b. <.036. IFN beta-1a 30 mcg IM QW. 36% Abbreviations: EOD, every other day; IFN, interferon; IM, intramuscular; QW, once weekly; SC, subcutaneously. Durelli L, et al. Lancet. 2002;359:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}